Loading
Celldex Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Nov 2024.
Celldex Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Celldex Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Hampton, United States. The group dates from 1983. In the past year (18 October 2025 to 18 October 2026), 4 filings came from 4 insiders.
There is no open-market purchase to report; the filings show 1 sale worth €104k by 1 insider. At €104k, the sale published on 8 December 2025 by Jimenez Freddy A. is the largest of the period.
Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 4 filings, this issuer sits below that mark. Our records for Celldex Therapeutics, Inc. go back to 2021, with 2 purchases and 3 sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Key facts
Headquarters: Hampton, United States · Founded: 1983
Source: Wikidata (CC0).
Insider Decl.
41
Thresholds
n/a
Buy Volume
€304,800
2 ops. · all time
Sell Volume
€2M
3 ops. · all time
Who traded when
BuySaleFreddy A. Jimenez2 sales
Anthony S. Marucci1 buy
Since the insiders bought
- -11.6%Entry US$26.84 · Close at T+365 US$23.72
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Celldex Therapeutics, Inc. Strong Buy (bullish), based on 15 analysts. Average price target: US$58.07.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$42.61
Analyst consensus
15 analystsStrong buy
US$38.00Target US$58.07(+36%)US$100.00
Income statement
RevenueUS$1.5M
EBITDA-US$284M-18381% margin
Net income-US$258.8M-16748.0% margin
Valuation
PER (forward)-10.2x
P/Book5.4x
Beta0.84
Balance sheet & cash
Market capUS$3.3B
Total debtUS$2.3M
Free Cash Flow-US$213.7M
Debt / Equity1%
Profitability & ownership
ROE-43.9%
ROA-27.6%
% insiders0.3%
% institutions103.1%
Last declaration on 6 January 2026
Declarations41 total
4,817 shares@ US$10.388.7% of flowCommon StockSEC:0001709024-26-000002:0
8,333 shares@ US$9.0165100.0% of flowCommon StockSEC:0001214504-25-000007:0
4,166 shares@ US$29.09531.5% of flowCommon StockSEC:0001838114-25-000007:0
6,876 shares@ US$9.016520.4% of flowCommon StockSEC:0001646423-25-000007:0
341 shares@ US$23.95152.1% of flowCommon StockSEC:0001415889-25-022069:0
10,500 shares0Common StockSEC:0001415889-24-027329:0
11,500 shares@ US$26.8246.5% of flowCommon StockSEC:0001415889-24-026489:0
Canonical exit: 9 Feb 2025 (T+90)
3,201 shares@ US$9.01655.5% of flowCommon StockSEC:0001415889-24-017363:0
30,000 shares@ US$10.3857.7% of flowCommon StockSEC:0001415889-24-017362:0
15,000 shares@ US$2.712.2% of flowCommon StockSEC:0001415889-24-016651:0
45,000 shares@ US$35.263284.2% of flowCommon StockSEC:0001415889-24-016344:0
7,500 shares@ US$10.3814.2% of flowCommon StockSEC:0001415889-24-016345:0
9,540 shares@ US$10.3827.6% of flowCommon StockSEC:0001415889-24-015950:0
6,289 shares@ US$9.016525.2% of flowCommon StockSEC:0001415889-24-015544:0
8,006 shares@ US$10.3823.1% of flowCommon StockSEC:0001415889-24-015542:0
20,625 shares@ US$2.7820.0% of flowCommon StockSEC:0001415889-24-015543:0
25,000 shares@ US$10.3849.1% of flowCommon StockSEC:0001415889-24-015147:0
34,445 shares@ US$2.7817.6% of flowCommon StockSEC:0001415889-24-015137:0
29,068 shares@ US$2.7836.2% of flowCommon StockSEC:0001415889-24-015148:0
10,750 shares@ US$2.7816.5% of flowCommon StockSEC:0001415889-24-015138:0
4,166 shares@ US$9.016510.6% of flowCommon StockSEC:0001415889-24-003891:0
10,750 shares@ US$2.785.5% of flowCommon StockSEC:0001415889-24-000592:0
16,860 shares@ US$2.78100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012301:0
19,000 shares@ US$10.3811.2% of flowCommon StockSEC:0001415889-22-008895:0
31,312 shares@ US$2.7851.2% of flowCommon StockSEC:0001415889-22-008896:0
25 of 41 declarations
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a U.S.-listed biotechnology company trading on the NASDAQ under the ticker CLDX, and its headquarters are in Hampton, New Jersey, United States. For French-speaking investors in France, Belgium, and Switzerland, Celldex should be viewed as a specialized immunology biotech rather than a diversified pharmaceutical company. Its investment case is driven primarily by clinical development execution, trial readouts, and the company’s ability to fund late-stage programs, rather than by current commercial sales. ([ir.celldex.com](https://ir.celldex.com/investor-relations?utm_source=openai))
Founded in 1991, Celldex has gradually transformed from a broader biotech platform into a more focused company centered on immunology and antibody-based therapies. Management describes the strategy as aiming to realign the immune response, with a focus on allergic, inflammatory, and autoimmune disorders. That strategic narrowing improves thematic clarity, but it also means the company remains highly dependent on a limited number of clinical assets. In equity terms, Celldex is still a development-stage biotechnology name with elevated binary risk and meaningful upside if its lead programs continue to perform. ([ir.celldex.com](https://ir.celldex.com/investor-relations?utm_source=openai))
Read moreShow less
The key value driver is barzolvolimab, a KIT-targeting antibody designed to affect mast cells, which are central to several urticaria and allergic disease pathways. Recent company disclosures indicate encouraging Phase 2 data in chronic spontaneous urticaria, cold urticaria, and symptomatic dermographism. In May 2026, Celldex reported that enrollment in both Phase 3 chronic spontaneous urticaria studies, EMBARQ-CSU 1 and 2, had been completed six months ahead of guidance, with top-line data expected in Q4 2026 and a BLA submission planned for 2027. The pipeline also includes CDX-622, which is being evaluated in a Phase 1 proof-of-mechanism study in asthma. ([ir.celldex.com](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-data-demonstrating-barzolvolimab-improves?utm_source=openai))
From a competitive standpoint, Celldex operates in a crowded immunology and allergy market populated by large-cap pharmaceutical companies and specialty biotech peers. Its differentiation lies in mechanism innovation and the possibility of demonstrating first-in-class or best-in-disease efficacy in symptomatic, high-burden indications. The flip side is that Celldex does not yet have a broad commercial portfolio, so valuation is likely to remain highly sensitive to clinical milestones, safety data, and financing decisions. ([ir.celldex.com](https://ir.celldex.com/investor-relations?utm_source=openai))
Geographically, the company’s footprint is almost entirely U.S.-based, with locations in New Jersey, Connecticut, and Massachusetts. Its operations are concentrated on research, development, and scientific collaboration, with no major international commercial footprint disclosed in the recent materials reviewed. Recent headline events include a $345 million gross follow-on equity offering closed in April 2026 and multiple conference presentations highlighting barzolvolimab data in 2025 and 2026. For investors, Celldex remains a classic NASDAQ-listed U.S. biotech story: scientifically promising, clinically driven, and inherently dependent on execution over the next several quarters. ([ir.celldex.com](https://ir.celldex.com/investor-relations?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
